STPs and Pharma: The great transformation
Sustainability and Transformation Plans (STPs) are set to create upheaval in the NHS – and in the pharma industry too
PharmaTimes -
September 2017
As the NHS goes, so goes pharma – so when the government talks about ‘transforming’ the health service, the industry better listen. Our cover feature this month (p33) focuses on sustainability and transformation plans (STPs), the ambitious-yet-controversial proposals for innovative, localised solutions to the NHS’s myriad problems. How can pharma best respond to these?
Meanwhile, this month’s SmartViews section opens with two more articles looking at the NHS – one asking how new caps on expenditure will affect pharma sales (p16), the other looking behind the mask of recent reports on the NHS’s strengths (p21).
On the industry side of things we’ve got an issue packed with commentary and analysis on the latest cutting-edge developments in pharma. On p24 we ask if the genomic revolution is all it’s hyped up to be, and on p26 we look at what a recent court ruling means for the ongoing issue of biosimilars and secondary use patents.
It seems that the hottest topic on everybody’s lips, though, is the potential of artificial intelligence in pharma R&D, and our exclusive interview with AI expert Jackie Hunter (p30) asks what this actually means in practice.
Digital edition sponsored by
September 2017 - magazine highlights
Intelligent design
PharmaTimes speaks to AI expert Jackie Hunter about the future of these technologies in R&D
Hollow Victory?
The NHS scores better than many other countries in terms of access to health – until you take outcomes into account
Clearing the way of secondary patents
The unusual circumstances of Fujifilm and AbbVie’s Humira patent case and its potential impacts on the market
Going public
Jaak Peeters, head of Johnson & Johnson Global Public Health, on pharma’s role in supporting global health, fighting epidemics and making medicines accessible
A reality check for the genomic revolution
Inside the technological, legislative and financial checks on the rise of genome-based medicine
Feeling the squeeze?
Paul Midgley, director of NHS Insight at Wilmington Healthcare, explains how Capped Expenditure Processes (CEP) will impact both NHS services and pharma sales
Embracing programmatic advertising
How targeted digital advertising could help pharma marketers avoid some of the industry’s most common pitfalls
Payment power
How to become investigator sites’ payments sponsor of choice
